^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Thymidine kinase stimulant

    Related drugs:
    11d
    GVO-1102: Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, GenVivo, Inc. | Recruiting --> Active, not recruiting | N=124 --> 37
    Enrollment closed • Enrollment change
    |
    GEN2 • Valcyte (valganciclovir)
    5ms
    PrTK03: Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (clinicaltrials.gov)
    P3, N=711, Active, not recruiting, Candel Therapeutics, Inc. | Trial completion date: Dec 2024 --> Dec 2030 | Trial primary completion date: Dec 2024 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    ProstAtak (aglatimagene besadenovec)
    5ms
    Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=12, Completed, Candel Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    ProstAtak (aglatimagene besadenovec)
    5ms
    Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) (clinicaltrials.gov)
    P2, N=187, Active, not recruiting, Candel Therapeutics, Inc.
    Trial completion date
    |
    ProstAtak (aglatimagene besadenovec)
    10ms
    GMCI, Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade Gliomas (clinicaltrials.gov)
    P1, N=41, Completed, Candel Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    Opdivo (nivolumab) • temozolomide • ProstAtak (aglatimagene besadenovec)
    10ms
    Dynamic tracking of tumor microenvironment modulation using Kaede photoconvertible transgenic mice unveils new biological properties of viral immunotherapy. (PubMed, Cancer Res Commun)
    Collectively, these data defined at least two temporally distinct pathways underpinning the mechanism of action of CAN-2409 action that overcome cell exhaustion and decreases immune suppression. The results also support the rationale for future clinical trials of CAN-2409 treatment combined with anti-CTLA-4 antibody therapy.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    ProstAtak (aglatimagene besadenovec)
    12ms
    Phase 1 Study of GEN2 in Patients with Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Recruiting, GenVivo, Inc. | N=91 --> 124
    Enrollment change • Metastases
    |
    GEN2 • Valcyte (valganciclovir)
    1year
    GEN2 Directed Cancer Immunotherapy Trial (clinicaltrials.gov)
    P1, N=61, Completed, GenVivo, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Dec 2023 | Trial primary completion date: Jun 2024 --> Dec 2023
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    GEN2
    over1year
    Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=91, Recruiting, GenVivo, Inc.
    New P1 trial • Metastases
    |
    GEN2 • Valcyte (valganciclovir)
    over1year
    GEN2 Directed Cancer Immunotherapy Trial (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, GenVivo, Inc. | Recruiting --> Active, not recruiting | N=122 --> 61 | Trial primary completion date: Dec 2023 --> Jun 2024
    Enrollment closed • Enrollment change • Trial primary completion date • Metastases
    |
    GEN2
    almost2years
    CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Candel Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Checkpoint inhibition
    |
    ProstAtak (aglatimagene besadenovec)
    2years
    Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma (clinicaltrials.gov)
    P2, N=52, Completed, Candel Therapeutics, Inc. | Phase classification: P2a --> P2
    Phase classification • Combination therapy • Gene therapy
    |
    temozolomide • ProstAtak (aglatimagene besadenovec)